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Using L-PYS]methionine labeling, SDS-PAGE and Northern blot analysis of sucrase-isomaltase mRNA, two different 
concentrations of monensin were used to delineate in Caco-2 cells the effect of the drug on the conversion of the high 
mannose to the complex form of sucrase-isomaltase from its dual effect on the biosynthesis of the enzyme and on the 
rate of glucose consumption. At 0. I PM the drug has no effect on the rate of glucose consumption and, although it inhibits 
the conversion of the high mannose to the complex form of the enzyme, it has no effect on the level of sucrase-isomaltase 
mRNA and on the amount of neosynthesized enzyme. At I FM, in addition to its inhibiting effect on the maturation 
of the enzyme, monensin provokes concomitantly an increase in the rate of glucose consumption and a decrease in the 
level of sucrase-isomaltase mRNA and in the amount of neosynthesized enzyme. All these effects are reversible within 
48 h after removal of the drug. 
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1. INTRODUCTION 
Monensin has been shown to block the process- 
ing of newly synthesized glycoproteins at the site of 
the Golgi complex in a variety of systems [l-5]. In 
normal small intestinal [6] and kidney cells [7] it in- 
hibits the conversion of the high mannose to the 
complex form of brush border-associated 
hydrolases, these enzymes being known to be 
highly glycosylated glycoproteins [8]. In a previous 
investigation on the effects of monensin on the 
processing of two representative microvillar 
hydrolases in the enterocyte-like human colon car- 
cinoma cell line Caco-2, namely sucrase-isomaltase 
and dipeptidylpeptidase-IV, we found that, in ad- 
dition to its inhibiting effect on the maturation of 
both enzymes, monensin also produced two unex- 
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petted effects: a decreased expression of sucrase- 
isomaltase, but not of dipeptidylpeptidase-IV, and 
an increased glucose consumption [9]. In view of 
other results obtained either in Caco-2 [lo], or in 
HT-29 cells [ll, 121, which suggested that, in these 
cells, glucose metabolism could interfere 
specifically with the expression of sucrase- 
isomaltase, it had been hypothesized that the im- 
pairment of the expression of the enzyme induced 
by monensin could be related to its effect on 
glucose consumption [9]. In this earlier work 
however we used a high concentration of monensin 
(10 PM) [9]. The purpose of the present work was 
to investigate: (i) by using lower concentrations of 
the drug, whether it was possible to delineate the 
effect of monensin on the processing of the enzyme 
from the effects on both its expression and glucose 
consumption; (ii) by using a cDNA clone of human 
intestinal sucrase-isomaltase r cently isolated [ 131, 
whether the impairment of the expression of the 
enzyme was at the mRNA level; (iii) the reversibili- 
ty of these effects. 
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2. MATERIALS AND METHODS 
Culture of Caco-2 cells, treatment with monensin and L- 
[“S]-methionine labeling were as in [9]. Preparation of cell 
homogenates was as in [lo]. Treatment with endo-fl- 
acetylglucosaminidase H (Endo-H), SDS-PAGE and 
fluorography were performed as in [9,14], except that rabbit 
polyclonal antibodies raised against sucrase-isomaltase from 
Caco-2 cells were used as in [12]. The cDNA clone for human 
intestinal sucrase-isomaltase psi2 [ 131 was obtained from D. 
Swallow (The Galton Laboratory, MRC, London). The cDNA 
clone for P-actin, Cl41 [15] was obtained from S. Alonso (ln- 
stitut Pasteur, Paris). The corresponding cDNA probes were 
labeled with ‘*P using multiprime DNA labeling system (Amer- 
sham International, England). Total RNA was isolated by ex- 
traction with guanidium isothiocyanate and centrifugation 
through CsCl gradient as in [16]. Aliquots (20pg) of total RNA 
were fractionated by electrophoresis on 1% agarose gels after 
denaturation in 1 M glyoxal [17]. Fractionated samples were 
transferred to Hybond N (Amersham), prehybridized in the 
presence of 50% formamide at 42°C [17], and hybridized with 
“P-labeled probes for 24 h at 42°C in the presence of 40% for- 
mamide and 10% Dextran sulfate. Blots were washed twice in 
2 x SSC, 0.1% SDS at room temperature, then once in 
0.1 x SSC, 0.1% SDS at 5O”C, and once more in 0.1 x SSC, 
0.1% SDS at 70°C for 15 min. Glucose consumption was 
measured as in [9]. 
3. RESULTS 
In order to determine the lowest concentration 
of monensin responsible for an increase in the rate 
of glucose consumption, post confluent Caco-2 
cells (day 16) were treated for two consecutive 
periods of 24 h with decreasing concentrations of 
monensin. Results reported in fig.1 show that the 
drug has no effect at 0.1 PM, whereas it increases 
the rate of glucose consumption by 40% at 1 ,uM. 
This effect on glucose consumption is reversible 
within 24 h after removal of the drug. 
Labeling of the cells with L-[35S]methionine was 
performed using the same protocols as in fig. 1. As 
shown in fig.2 both concentrations of monensin in- 
hibit the conversion of the high mannose to the 
complex form of the enzyme; however, while the 
total amount of neosynthesized enzyme is similar 
to the control in cells treated with 0.1 ,xM monen- 
sin, there is a marked decrease in the amount of 
neosynthesized enzyme in cells treated with 1 PM 
monensin. As also shown in fig.2, all these effects, 
including the decrease in the amount of neosyn- 
thesized enzyme, are totally reversible within 48 h. 
As shown in figs 3 and 4, the effects of monensin 
on the expression of the neosynthesized enzyme are 
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Fig. 1. Effect of monensin on the rate of glucose consumption 
in Caco-2 cells. Time 0 is 16 days in culture. Monensin was 
added to the culture medium for two consecutive periods of 
24 h and then removed. (0) Control cells; (0) 0.1 pM 
monensin; (A) 1 pM monensin. Results are expressed as % of 
control. The rate of glucose consumption in control cells is 
400 k 20 nmol/h per mg protein. 
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Fig.2. Fluorograms of SDS-PAGE of sucrase-isomaltase 
immunoprecipitated from cell homogenates of Caco-2 cells, 
treated or not with monensin. Cells were labeled for 3 h with L- 
[“Slmethionine. lmmunoprecipitates were treated (+) or not 
( - ) with Endo-H. As in fig.1, Caco-2 cells (day 16 in culture) 
were treated for two consecutive periods of 24 h and labeled at 
the end of this treatment: (a) control cells; (b) cells treated with 
0.1 pM monensin; (c) cells treated with 1 ,uM monensin. Last 
three lanes represent the results obtained 48 h after removal of 
monensin; (d) control cells; (e) 0.1 PM monensin; (f) 1 pM 
monensin. Note in (b) and (c) the absence of the Endo-H 
resistant form of the enzyme and, in (c) only, a decreased 
staining of the band. Also note that in (e) and (f) the pattern is 
back to the control, including the intensity of labeling in (f). In 
all conditions the same amount of proteins was used for 
immunoprecipitation (200 pg). Since the activity of sucrase- 
isomaltase, and supposedly its biosynthesis, increases rapidly 
within the period of this experiment (i.e. between 16 and 20 
days) [lo], control cells were assayed at both times: note that 
the overall amount of neosynthesized enzyme is lower in (a) 
than in (d). 
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Fig.3. Northern blot of total RNA isolated from control (a,d) 
and monensin treated Caco-2 cells after 48 h of treatment, and 
48 h after removal of the drug (same conditions and letter 
labeling as in fig.2). Blot was hybridized with the probes for 
sucrase-isomaltase (upper band) and&actin (lower band). Note 
the decrease of sucrase-isomaltase mRNA level in cells treated 
with 1 gM monensin (c) but not with 0.1 pM (b) and the 
reversion to the control level 48 h after removal of the drug (f). 
Also note the stability of actin mRNA levels used here as a 
quantitative control. 
associated with parallel effects on the level of 
sucrase-isomaltase RNA. At 0.1 PM, monensin has 
no effect, whereas at 1 ,uM there is a marked 
decrease in the level of sucrase-isomaltase mRNA 
after 48 h. This impairment of the expression of 
sucrase-isomaltase mRNA in cells treated with 1 
PM monensin is reversible as, 48 h after removal of 
the drug, its level is back to the normal. 
Fig.4. Dot blots of glyoxal denatured RNA from Caco-2 cells 
treated or not with 1 pM monensin hybridized to (6a) the probe 
for sucrase-isomaltase and (b) the probe for /3-actin. Dot blots 
were performed at the indicated times of treatment (Mi) and of 
removal (M-) of the drug. RNA from control cells corresponds 
to the beginning of the treatment (CO), 48 h of treatment (C48) 
and 48 h after removal of the drug (C-48). The numbers at the 
bottom &g) refer to the amounts of RNA applied. Note the 
progressive decrease of sucrase-isomaltase mRNA levels in cells 
treated with 1 PM monensin as compared to the corresponding 
control, contrasting with the stability of /Sactin level. Also note 
that the sucrase-isomaltase mRNA level has returned to the 
control value 48 h after removal of the drug. The fi-actin 
controls were similar under all conditions, even with shorter 
exposure times (not shown). 
4. DISCUSSION 
The present results show that if the inhibition of 
the conversion of the high mannose to the complex 
form of sucrase-isomaltase is dose-independent in 
the range of concentrations of monensin used here 
and in our previous work [9], i.e. O.l-lOpM, the 
dual effect on the expression of the enzyme and on 
glucose consumption is dose-dependent. 
That the decreased level of neosynthesized en- 
zyme, when observed, is paralleled by a decreased 
level of sucrase-isomaltase mRNA, suggests that 
monensin provokes an overall inhibition of the 
biosynthesis of the enzyme. Interestingly this effect 
is strictly concomitant with the effect of the drug 
on the rate of glucose consumption: at 0.1 PM the 
drug has no effect on either glucose consumption 
or the levels of sucrase-isomaltase mRNA and the 
amount of neosynthesized enzyme, whereas at 1 
PM, as well as at 10 PM [9], the inhibition of the 
biosynthesis of the enzyme is paralleled by an in- 
creased rate of glucose consumption. That there is 
a close relationship between both effects is further 
supported by the concomitant decrease to the nor- 
mal rate of glucose consumption and increase to 
the control values of the levels of mRNA and 
amount of neosynthesized enzyme when monensin 
is removed from the culture medium. 
These results raise a number of questions as to 
the mechanisms involved in the inhibiting effect of 
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monensin on the biosynthesis of sucrase- 
isomaltase. A first question, with no current 
answer, is whether the decreased level of sucrase- 
isomaltase mRNA is the result of an instability of 
this mRNA or of an impairment of its transcrip- 
tion. Another question, to which no direct answer 
can yet be given, is whether the dual effect of the 
drug on glucose consumption and sucrase- 
isomaltase mRNA level and biosynthesis is the 
result of a cause-effect relationship or whether 
both effects are independent. A last question is 
whether the results observed here can be genera- 
lized to other systems. In a previous study by 
Danielsen et al. [6] these authors had shown that 
monensin, at 1 yM, had no effect on the amount 
of neosynthesized sucrase-isomaltase in cultured 
explants of pig intestinal mucosa. Whether the dif- 
ference of effect of monensin in Caco-2 cells, as 
compared to normal cells [6], is a consequence of 
the malignant state of the cells is questionable. It 
must be reminded that the metabolism of glucose 
in malignant epithelial cells, including in colon 
cancer cells [18,19], is altered. It is not unlikely 
that the particular effects observed in Caco-2 cells 
could be a consequence of the action of monensin 
on an altered metabolism of glucose. Such an ac- 
tion would not happen in cells with a normal 
regulation of glucose metabolism, such as normal 
intestinal cells. 
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